•  
  •  
 

Keywords

ROS-1 positive NSCLC, Crizotinib, Lazarus response, Pulmonary embolism, Anticoagulant

Abstract

A 57-year-old woman with a ROS1-rearranged NSCLC patient demonstrated a Lazarus response to crizotinib but later developed recurrent pulmonary embolism (PE) with right ventricular (RV) failure. This incident highlights the potential crizotinib-related thrombotic risk and the need for appropriate monitoring of vascular complications, particularly in limited-option settings such as Thailand.

References

1. Xu H, Zhang Q, Liang L, et al. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with di erent ROS1 fusion variants. Cancer Med. 2020;9(10):3328–3336.

2. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1- rearranged non-small-cell lung cancer. New Engl J Med. 2014;371(21):1963–1971.

3. Shea M, Huberman MS, Costa DB, et al. Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation–positive lung adenocarcinoma. J Thorac Oncol. 2016;11(7):e81–e82.

4. Vitale C, D’Amato M, Calabrò P, Stanziola AA, Mormile M, Molino A. Venous thromboembolism and lung cancer: A review. Multidiscip Respir Med. 2015;10(1).

5. Chiari R, Ricciuti B, Landi L, et al. ROS1-rearranged nonsmall- cell lung cancer is associated with a high rate of venous thromboembolism: Analysis from a phase II, prospective, multicenter, two-arms trial (METROS). Clin Lung Cancer. 2020;21(1):15–20.

6. Zhang H, Song Y, Xia F, et al. Adverse event profile of crizotinib in real-world from the FAERS database: A 12-year pharmacovigilance study. BMC Pharmacol Toxicol. 2025;26(1).

7. Qi Y, Wang X, Guo T, You T, Wang P. Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: A systematic review and network meta-analysis. BMJ Open. 2024;14(9):e078173.

8. Lee A, Howell VM, Itchins M, Wheeler HR, Pavlakis N. ROS1-rearranged non–small-cell lung cancer, factor V leiden, and recurrent venous thromboses. Clin Lung Cancer. 2018;19(5):457–459.

9. Beninato T, Russo GL, Garassino MC, Braud FD, Platania M. Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: A case report. Tumori J. 2020;106(6):NP41–NP45.

10. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7): e334–e347.

Download

Share

COinS